Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
18,951 Deaths · 90,081 Hospitalizations · 118,932 Urgent Care · 199,491 Doctor Office Visits · 2,509 Anaphylaxis · 6,353 Bell's Palsy · 2,064 Miscarriages · 9,422 Heart Attacks · 28,490 Myocarditis · 18,274 Permanently Disabled · 9,241 Thrombocytopenia · 15,197 Life Threatening · 36,645 Severe Allergic Reaction · 8,214 Shingles · 5,236 Myocarditis/Pericarditis · 3,701 Thrombocytopenia/Low Platelet ·
·
18,951 Deaths · 90,081 Hospitalizations · 118,932 Urgent Care · 199,491 Doctor Office Visits · 2,509 Anaphylaxis · 6,353 Bell's Palsy · 2,064 Miscarriages · 9,422 Heart Attacks · 28,490 Myocarditis · 18,274 Permanently Disabled · 9,241 Thrombocytopenia · 15,197 Life Threatening · 36,645 Severe Allergic Reaction · 8,214 Shingles · 5,236 Myocarditis/Pericarditis · 3,701 Thrombocytopenia/Low Platelet ·
·